NovoCure IPO: Our Pick Of The Week
NovoCure (NASDAQ: NVCR) is a commercial stage cancer treatment company set for an IPO offering 12.5 million shares of common stock with a price target of $26-$29 per share. The company scheduled a $344 million from the IPO with an estimated market cap of $2.4 billion. The underwriters for the IPO include Deutsche Bank, JPMorgan Chase,…